Figure 6From: A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacyImmune cell infiltration in xenograft tumors measured by immunohistochemistry. Mouse xenograft tumors treated with trastuzumab, single hinge cleaved trastuzumab (scIgG-T), and the isotype control were fixed in 4% paraformaldehyde. Six immunohistochemistry slides were prepared from the paraffin-embedded tissues of two mice from each treatment group. Monocytes/macrophages were stained using the anti-mouse integrin αM/CD11b and anti-mouse F4/80 antibodies. (A) Representative images (×40) of CD11b-stained tumor tissue and positive-stained immune cells indicated by black arrows. Right bar graph: average number of CD11b-positive cells per tumor tissue slide (n = 6). Pairwise t test used to compare different treatment groups. **P < 0.005. (B) Representative images (×40) of F4/80-stained tumor tissues from different treatment groups. Right bar graph: Average number of positive stained cells detected per tissue slides (n = 6). Pairwise t test used to compare different treatment groups. **P < 0.005.Back to article page